bluuebunny/crossref_metadata_2025_split huggingface dataset:
Abstract P5-16-11: Intraoperative central nipple biopsy in subcutaneous mastectomies - A retrospective analysis of 200 patients
Authors: Eichler C , Stephan S , Thangarajah F , Puppe J , Mathias W 
Published: May 2019

Abstract
Background: Subcutaneous nipple sparing mastectomies (NSM) are an important tool in modern oncoplastic surgery. Especially when an immediate implant-based reconstruction (IBR) is desired, clean margins are of the utmost importance. Central nipple biopsies during surgery serve two main purposes. Most importantly, it is hypothesized that a general recurrence risk reduction occurs due to elimination of glandular and ductal components within the nipple. In addition, intraoperative pathological evaluation of this biopsy may increase clean margin resection rates. This trial aimed to evaluate complication rates, local recurrence and clean margin resection rates in a head-to-head retrospective manner.
Methods: Starting in 2015, intraoperative central nipple biopsy in NSM with IBR was introduced at the Municipal Breast Cancer Centre Cologne, Holweide, Germany. This trial evaluates global complication rates (necrosis, implant loss, seroma and hematoma), long term local recurrence and clean margin status for cohort 1 (n=100) SSM with nipple biopsy vs. cohort 2 (control, n = 100) without nipple biopsy. In case of an involved central nipple biopsy, the nipple areola complex was removed. This analysis is a single center, multi-surgeon, retrospective, head to head analysis. Median follow-up is three years. All IBR procedures used an epipectoral implant pocket.
Results: Global complication rates did not differ significantly between both cohorts. There was no increased rate of implant loss and or revision surgery. Within the medium three-year follow-up there was no case of local recurrence within nipple areola complex for both cohorts. An Involved central nipple biopsy was however found in 2% (n=2 /100) of the performed SSM procedures leading to the immediate removal of the nipple areola complex. Surgical time did not increase with central biopsy. A significantly higher rate of re-surgery due to involved margins was shown in the control cohort.
Conclusions: This analysis showed that intraoperative evaluation of the ductal components of the nipple is a safe procedure. At least 2% of the patients showed an immediate advantage of this procedure since clean margins were obtained by removing the nipple areola complex during the same surgery. The medium follow-up showed no significant difference in local recurrence. We therefore strongly, recommend a central nipple biopsy for all NSM procedures.
Citation Format: Eichler C, Stephan S, Thangarajah F, Puppe J, Mathias W. Intraoperative central nipple biopsy in subcutaneous mastectomies - A retrospective analysis of 200 patients [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P5-16-11.
Abstract P5-16-13: First results of the NOGGO-AWOGyn observational study: Skin and nipple sparing mastectomy and breast reconstruction with an implant and Epiflex®
Authors: Blohmer J-U , Ankel C , Faridi A , Krause-Bergmann B , Neumann C , Schnuppe K , Beier L , Mau C , Strittmatter H-J , Gerber-Schäfer C , Bauer L , Paepke S 
Published: May 2019

Abstract
Acellular dermal matrices (ADM) were used to cover the implant to reduce implant rotations and to improve esthetic results. Current retrospective data on complication rates are heterogeneous. Prospective data are rare. Primary objective was to evaluate the explantation rate.
11 German sites, with experience in breast reconstruction using ADM, have been selected for participation in this study. Patients were enrolled according to predefined in- and exclusion criteria into two cohorts: group A - primary reconstruction and group B - secondary reconstruction after capsular contracture.
After documentation of baseline characteristics and surgical parameters, endpoints such as rate of seroma, red breast syndrome, infection and explantation were assed at 1 day, 7 days, 1 month, 3, 6 and 12 months after surgery. In addition, patient- and surgeon-satisfaction were recorded.
Data of 83 patients were analyzed (A: 50, B: 33). In 29 patients Epiflex was used bilaterally, so that it was used 112-times in total. The average age of the patient was 45.1 years (A: 41.5; B: 50.3), the average BMI was 22.2 (A: 22.3; B: 22.1).
In total, 17.0 % seromas (A: 19.4 %; B: 12.5 %), 10.7 % red breast syndrome (A: 9.7 %; B: 12.5 %), 4.5 % infections (A: 6.9 %; B: 0 %) and 5.4 % explantations (A: 6.9 %; B: 2.5 %) were observed.
During the average observation period of 8 month, the satisfaction of the patients and surgeons was high at all measured time points. On a scale from (1 - very satisfied to 6 - not satisfied) the satisfaction of patients and surgeons was 2.3 (A: 2.3; B:1.9) and 2.0 (A: 2.2; B: 1.8) respectively.
Our data show, that both patients and surgeons are generally satisfied with the outcome of breast reconstruction using ADM. Complication rates were adequate and commonly lower in secondary reconstructions.
Citation Format: Blohmer J-U, Ankel C, Faridi A, Krause-Bergmann B, Neumann C, Schnuppe K, Beier L, Mau C, Strittmatter H-J, Gerber-Schäfer C, Bauer L, Paepke S. First results of the NOGGO-AWOGyn observational study: Skin and nipple sparing mastectomy and breast reconstruction with an implant and Epiflex® [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P5-16-13.
Abstract P5-16-16: Reconstructive breast surgery with partially absorbable bi-component Seragyn® BR soft mesh: An outcome analysis
Authors: Machleidt A , Schmidt-Feuerheerd N , Blohmer J-U , Ohlinger R , Küper J , von Waldenfels G , Dittmer S , Paepke S , Klein E 
Published: May 2019

Abstract
Objective:
Synthetic meshes and acellular dermal matrices are increasingly used in implant based breast reconstruction. The objective of this study was to determine the incidence and severity of complications following the implantation of the partially absorbable bi-component soft mesh SERAGYN ® BR and assess risk factors for adverse operative outcomes.
Methods:
A retrospective clinical study was performed: The SERAGYN ® BR soft mesh was utilized in 148 operations (skin-sparing mastectomy, nipple-sparing mastectomy, breast conserving surgery, secondary reconstruction after mastectomy) in four different institutions in Germany from
June 2012 to February 2014. We analyzed whether the results were affected by tumor morphology (e.g. grading), patient characteristics and co-morbidities, previous surgery or therapies and use of alloplastic materials.
Results:
The SERAGYN ® BR soft mesh was successfully implanted in 131 of 148 operations. The rate of reconstructive failure was 11.5 %. The most common complication was seroma (25.7 %), followed by hematoma and skin infection (each 14.2%). Wound healing issues were detected in
13.5% cases, secondary wound infections in 10.8%. 83.8% of operations had no severe complications. Independent predictors for reconstructive failure were wound healing issues, nipple- or skin necrosis, wound- or skin infections, a high volume of excised tissue, hematomas, seromas and sentinel lymph node excisions. A higher body mass index was correlated with a higher
rate of infection.
Conclusion:
SERAGYN ® BR mesh can be used successfully in breast reconstructive surgery. Rates of major complications or reconstructive failure are comparable to the use of other synthetic or biological meshes.
Citation Format: Machleidt A, Schmidt-Feuerheerd N, Blohmer J-U, Ohlinger R, Küper J, von Waldenfels G, Dittmer S, Paepke S, Klein E. Reconstructive breast surgery with partially absorbable bi-component Seragyn® BR soft mesh: An outcome analysis [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P5-16-16.
Abstract P5-16-17: Titanium-coated polypropylene mesh for immediate implant-based breast reconstruction – Our initial experience
Authors: Munir A , Holt S , Huws A , Khan S , Shariaha Y , Khawaja S 
Published: May 2019

Abstract
Background: The use of titanium-coated polypropylene mesh (TCPM) is an alternative to a-cellular dermal matrix for the implant based breast reconstruction by providing extra implant coverage especially in the lower half. The aim of our study was to analyze short-term outcomes of TCPM based implant breast reconstruction and compare the patient- and procedure-related factors to implant loss and surgical complications.
Methods: Between 2013and 2016, implant breast reconstructions after conservative mastectomies using TCMP was performed in 50 patients (with 58 reconstructions). Complications were divided into major (need for additional surgery), minor (conservative treatment), and implant loss. Univariate analyses were performed to determine the influence of the patient- and procedure-related factors on postoperative complications and implant loss.
Results: Fifty patients had therapeutic mastectomies with 8 of them also had contra lateral risk reducing mastectomies. With median follow-up of 17.5 months, four of 50 patients had implant loss. Reasons for implant loss were skin necrosis in 2 cases, infection in 1 case and necrosis with infection in another case. One of these patients had a revised reconstruction one year later. One additional patient required implant replacement because of capsule contracture. No risk factors were observed for patient-associated complications. Univariate analysis revealed an increased risk for implant loss in patients with skin necrosis (p &lt; 0.01).
Conclusions: This titanium-coated polypropylene mesh shows acceptable complication rates and its use in immediate implant breast reconstruction is safe and effective.
Citation Format: Munir A, Holt S, Huws A, Khan S, Shariaha Y, Khawaja S. Titanium-coated polypropylene mesh for immediate implant-based breast reconstruction – Our initial experience [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P5-16-17.
Abstract P5-16-18: Oncologic outcomes and reconstruction quality of immediate autologous breast reconstruction in intermediate and locally advanced breast cancer
Authors: Yoon WS , Yang DS , Son GS , Woo SU , Kim D-W , Dhong E-S , Chang YW 
Published: May 2019

Abstract
Purpose: We analyzed oncologic outcomes and reconstruction quality in locally advanced stage breast cancer after performing immediate autologous breast reconstruction (IABR).
Methods: From 2007 to 2014, data of patients with stage II-III breast cancer of ≤ 70-years-old who received total mastectomy (TM) from two institutions were extracted. Exclusion criteria were: previous contralateral breast cancer, follow-up loss before adjuvant therapy completion, and artificial reconstruction. Patients were divided into two groups; 1) TM alone and 2) TM+IABR. Overall survival (OS) and loco-regional recurrence free survival (LRRFS) were calculated and minor revision, abnormal volume on CT, and breast height change were observed.
Results: Sixty-one of 188 patients received IABR after TM. Neoadjuvant chemotherapy and postoperative radiotherapy was done in 27 and 80 patients, respectively. Fifty-nine percent, 19.2%, and 21.8% of patients were in stage II, IIIA, and IIIB-C, respectively. Stage IIIB-C was the most important prognostic factor for OS and LRRFS. In a median of 56.8 follow-up months, 5-year TM and TM+IABR OS rate were 96.8% and 100% for stage II (P=0.324) and 57.6%, 95.5% and 91.7% for stage IIIA (P=0.698), and 62.5% for stage IIIB-C (P=0.544), respectively. Five-year TM and TM+IABR LRRFS were 98.1% and 95.7% for stage II (P=0.998)91.1% and 100% for stage IIIA (P=0.277), and 70.8% and 62.5% for stage IIIB-C (P=0.378), respectively. However, two locoregional failures after 5-years were developed in stage IIIB-C of TM+IABR at 71 and 94 months. Minor revisions 3 months of IABR, including two major complications, were done in 49.2%. The reduction of breast height was 21.2% (11/52) and 31.9% (15/47) in about 18 months and about 42 months observations after IABR, respectively. The volume of abnormal imaging was over 10 cc in 27.3% (15/55) on CT of 6 months after IABR. Although minor revisions, abnormal volume on CT, and breast height change were common, they were not related to therapeutic methods, including radiotherapy and tumor stage.
Conclusions: In about 5-years follow-up, IABR did not aggravate oncologic outcomes, and adjuvant radiotherapy was not closely related with quality of reconstruction. It must be considered, however, that absolute oncologic outcomes of advanced stage were not sufficient, and minor problems post-IABR were commonly developed.
Citation Format: Yoon WS, Yang DS, Son GS, Woo SU, Kim D-W, Dhong E-S, Chang YW. Oncologic outcomes and reconstruction quality of immediate autologous breast reconstruction in intermediate and locally advanced breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P5-16-18.
Abstract P6-01-01: Immunohistochemical staining and in vitro analysis of HER2-positive breast cancer using trastuzumab and pertuzumab to develop an appropriate tracer in image-guided surgery
Authors: Otsubo R , Kuppen PJ , Bhairosingh S , Vahrmeijer AL , Smit VT , Nagayasu T , van de Velde CJ , Sier CF 
Published: May 2019

Abstract
Background: Pre- and intraoperative visualization of cancer cells using monoclonal antibody-based multimodal tracers can demarcate tumor margins in breast-conserving surgery. We focused on trastuzumab (Tmab) to develop a tracer for HER2-positive breast cancer by conjugation with a fluorescent dye. However, whether Tmab can be used as an imaging tracer for patients who receive Tmab as neoadjuvant therapy (NAD) is unclear, because tumor-cell HER2 could be bound by NAD Tmab at the time of surgery. This study evaluated immunohistochemical (IHC) staining and in vitro experiments with Tmab and pertuzumab (Pmab) as primary antibodies to find a suitable tracer. Pmab has a different antigen epitope than Tmab.
Methods: We included 43 patients with HER2-positive breast cancer, who were treated between 2010 and 2016. The NAD cohort (n=10, with 26 lesions) received chemotherapy and Tmab before surgery. The Tmab-naïve cohort (n=33, with 95 lesions) did not receive chemotherapy or Tmab before surgery. We excluded NAD patients with pathological complete responses. We evaluated the lesions, using IHC with Tmab and Pmab. We also performed flow cytometry and fluorescent microscopic analysis (FMA) using Tmab and Pmab conjugated with a fluorescent agent for the HER2-negative MCF7 and HER2-positive HCC1954 cell lines, which were pre-treated with Tmab to model NAD conditions.
Results: IHC with anti-HER2 antibody showed positive staining in all patients. Tmab staining was less intense, but positive Tmab IHC reactions were detected on tumor cell membranes in 77.8% of lesions in the naïve cohort and 70.8% in the NAD cohort. Pmab staining was seen in 46.3% of naïve cohort lesions and 22.2% of NAD lesions. Notably, we observed cytoplasmic staining in 87.8% of Pmab-negative cases in the NAD cohort. Flow cytometry showed less Tmab binding than Pmab binding in HCC1954 cells. After 24 hours' pretreatment incubation with Tmab, FMA showed a clear decrease in Tmab binding from 73.3% (without pretreatment) to 5.7%(after pretreatment), and a smaller decrease in Pmab binding from 72.7% (without pretreatment) to 66.4% (after pretreatment) in HCC1954 cells.
Conclusions:Pmab might be a suitable tracer for image-guided surgery after NAD, but identifying a suitable tracer for HER2-positive breast cancer will require further study.
Citation Format: Otsubo R, Kuppen PJ, Bhairosingh S, Vahrmeijer AL, Smit VT, Nagayasu T, van de Velde CJ, Sier CF. Immunohistochemical staining and in vitro analysis of HER2-positive breast cancer using trastuzumab and pertuzumab to develop an appropriate tracer in image-guided surgery [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-01-01.
Abstract P6-02-03: Interpretation schema for optical coherence tomography images in breast tissue
Authors: Yemul KS , Zysk AM , Richardson AL , Tangella KV , Jacobs LK 
Published: May 2019

Abstract
Purpose
Optical coherence tomography (OCT) is an attractive technology for surgical imaging because it permits the real-time visualization of microscopic tissue morphology with a handheld probe without the need for exogeneous agents, tissue manipulation, ionizing radiation, or histological processing. While initial studies have shown that OCT is an effective margin-evaluation tool for breast conserving surgery (BCS), image interpretation and feature identification have not been directly studied. In this work, breast pathologies were assessed with a handheld OCT probe and the images were compared to histology.
Methods
Mastectomy and BCS specimens from 26 women were imaged with a handheld OCT probe, and histology slides from the same region were digitally photographed. OCT and histology images from the same region were paired by selecting the best structural matches. Because image characteristics in OCT are akin to those in ultrasound, descriptive OCT image feature terminology similar to that of ultrasound was developed. Each of these characteristics was used to select and describe OCT-histology image matches.
Results
In total, 2880 OCT images were acquired from 26 breast specimens, and 48 matching OCT-histology image pairs were identified. These matched image pairs illustrate tissue types including adipose tissue, dense fibrosis, fibroadipose tissue, blood vessels, regular and hyperplastic ducts and lobules, cysts, fibroadenoma, IDC, ILC, DCIS, calcifications, and biopsy cavities. Differentiation between pathologies was achieved by considering feature boundaries, interior appearance, posterior shadowing or enhancement, and overall morphologic patterns.
Conclusions
This is the first work to systematically catalog the features of breast OCT images. The results indicate that OCT can be used to identify important structures and distinguish between benign and malignant breast pathologies.
Citation Format: Yemul KS, Zysk AM, Richardson AL, Tangella KV, Jacobs LK. Interpretation schema for optical coherence tomography images in breast tissue [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-02-03.
Abstract P6-02-13: Withdrawn
Authors: Huang C-S , Fann JC-Y , Chen H-H , Hsu G-C , Ho M-F , Chen S-C , Chen Y-J , Chen S-T , Chen C-Y , Sheen-Chen S-M , Chang H-T , Yeh D-C , Chao M , Yeh H-T , Cheng L , Chen D-R , Chang Y-C , Chang K-J 
Published: May 2019

Abstract
This abstract was withdrawn by the authors.
Citation Format: Huang C-S, Fann JC-Y, Chen H-H, Hsu G-C, Ho M-F, Chen S-C, Chen Y-J, Chen S-T, Chen C-Y, Sheen-Chen S-M, Chang H-T, Yeh D-C, Chao M, Yeh H-T, Cheng L, Chen D-R, Chang Y-C, Chang K-J. Withdrawn [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-02-13.
Abstract P6-02-17: Hand-held impulse-radar detector for breast cancer: development and a pilot study
Authors: Sasada S , Masumoto N , Song H , Goda N , Kajitani K , Emi A , Kadoya T , Arihiro K , Kikkawa T , Okada M 
Published: May 2019

Abstract
Background: Microwave breast imaging, which using the difference in the dielectric properties between breast cancer and normal breast tissue, is a painless and non-radiation method. We have created a novel hand-held prototype of breast cancer detector using impulse-radar based imaging system, and conducted a pilot clinical study.
Methods: The detector consists of complementary metal-oxide-semiconductor (CMOS) integrated circuits covering the ultrawideband width from 3.1 to 10.6 GHz, which enable the generation and transmission of Gaussian monocycle pulse (GMP) trains and single port eight throw switching matrices (SP8T-SW) for controlling a 4×4 cross-shaped dome antenna array. The size of the detector was 19.1 × 17.7 × 18.8 cm. After evaluation using a breast tumor phantom and the resected breast specimens obtained through mastectomy, we recruited 5 patients with histologically confirmed breast cancers in the clinical study. The detector was placed on the breast with the patient in a supine position. The primary endpoint was a detection rate of breast cancers, and the secondary endpoints were positional accuracy and adverse event. This study was registered with the UMIN Clinical Trials Registry (UMIN000026181).
Results: The three-dimensional positions of the tumors in the imaging results using a phantom and resected specimens are consistent with the results of histopathology analysis. In the clinical study, all 5 targeted breast cancers were detected and were visualized at the sites confirmed by other diagnostic modalities. Among 5 tumors, one was not detected via mammography because of heterogeneously dense breast and another was a microinvasive carcinoma of invasive tumor size 0.5 mm. No study-related adverse events occurred.
Conclusions: We succeeded in creating a new device of hand-held impulse-radar detector for breast cancer. The detector has sufficient detective capability, is safe for clinical use, and might detect an early stage breast cancer. In the future, we will proceed with the development to clinical application.
Citation Format: Sasada S, Masumoto N, Song H, Goda N, Kajitani K, Emi A, Kadoya T, Arihiro K, Kikkawa T, Okada M. Hand-held impulse-radar detector for breast cancer: development and a pilot study [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-02-17.
Abstract P6-03-03: Withdrawn
Authors: Penzvalto Z , Chen JQ , Cardiff RD , Willis B , Hubbard NE , Piersigilli A , Borowsky AD 
Published: May 2019

Abstract
This abstract was withdrawn by the authors.
Citation Format: Penzvalto Z, Chen JQ, Cardiff RD, Willis B, Hubbard NE, Piersigilli A, Borowsky AD. Withdrawn [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-03-03.
Abstract P6-03-05: Not presented
Authors: Guangping L , Wei L , Xiang H , Shidai J , Dengshun M , Ziyi F , Jinhai T , Yongmei Y 
Published: May 2019

Abstract
This abstract was not presented at the conference.
Citation Format: Guangping L, Wei L, Xiang H, Shidai J, Dengshun M, Ziyi F, Jinhai T, Yongmei Y. Not presented [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-03-05.